FINWIRES · TerminalLIVE
FINWIRES

調査速報:パラマウント・スカイダンス社、2026年第1四半期にまちまちの業績を発表

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。PSKYの2026年第1四半期決算は、売上高が83億5,000万ドル(前年同期比2%増)となり、市場予想の71億9,000万ドルを上回りました。調整後EBITDAは前年同期比59%増の11億6,100万ドルに急増し、利益率は10.2%から15.8%に拡大しました。GAAPベースの希薄化後EPSは0.15ドルで、市場予想と一致し、新経営陣の下での事業の勢いを示しています。DTC(消費者直販)事業の好調ぶりを高く評価しており、Paramount+の売上高は前年同期比17%増の20億ドル、加入者数は全世界で7,960万人に達し、利益率は10%、ARPU(加入者1人当たり平均売上高)も10%増加し、黒字化を達成しました。経営陣は顧客向けテクノロジーの近代化を進めており、1月には全プランで価格改定を実施しました。テレビメディアは構造的な逆風に直面し、売上高は前年比6%減の37億ドルとなったものの、コスト管理の徹底により調整後EBITDAマージンが24%から29%に拡大し、高い収益性を維持した。スタジオ部門の売上高は、スカイダンスの統合により前年比11%増加し、経営陣はパラマウントとワーナー・ブラザースで最低30本の映画を劇場公開し、劇場を支援するために45日間の公開期間を設けることを約束した。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX
調査速報:パラマウント・スカイダンス社、2026年第1四半期にまちまちの業績を発表 | FINWIRES